Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Noninvasive identification of HER2-low-positive status by MRI-based deep learning radiomics predicts the disease-free survival of patients with breast cancer

Published:2023-08-19 Issue: Volume: Page:
ISSN:1432-1084
Container-title:European Radiology
language:en
Short-container-title:Eur Radiol

Author:

Guo Yuan,Xie Xiaotong,Tang Wenjie,Chen Siyi,Wang Mingyu,Fan Yaheng,Lin Chuxuan,Hu Wenke,Yang Jing,Xiang Jialin,Jiang Kuiming,Wei Xinhua,Huang Bingsheng,Jiang Xinqing^ORCID

Funder

National Natural Science Foundation of China

the Special Fund for the Construction of High-level Key Clinical Specialty (Medical Imaging) in Guangzhou

Guangzhou Key Laboratory of Molecular Imaging and Clinical Translational Medicine

Guangdong Basic and Applied Basic Research Foundation

Shenzhen-Hong Kong Institute of Brain Science-Shenzhen Fundamental Research Institutions

SZU Top Ranking Project - Shenzhen University

Guangzhou First People's Hospital Frontier Medical Technology Project

Science and technology Projects in Guangzhou

Publisher

Springer Science and Business Media LLC

Subject

Radiology, Nuclear Medicine and imaging,General Medicine

Link

https://link.springer.com/content/pdf/10.1007/s00330-023-09990-6.pdf

Reference37 articles.

1. Montemurro F, Delaloge S, Barrios C et al (2020) Trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer and brain metastases: exploratory final analysis of cohort 1 from KAMILLA, a single-arm phase IIIb clinical trial. Ann Oncol 31:1350–1358

2. Hurvitz S, Caswell-Jin J, McNamara K et al (2020) Pathologic and molecular responses to neoadjuvant trastuzumab and/or lapatinib from a phase II randomized trial in HER2-positive breast cancer (TRIO-US B07). Nat Commun 11:5824

3. Mamounas E, Untch M, Mano M et al (2021) Adjuvant T-DM1 versus trastuzumab in patients with residual invasive disease after neoadjuvant therapy for HER2-positive breast cancer: subgroup analyses from KATHERINE. Ann Oncol 32:1005–1014

4. Beyer I, Li Z, Persson J et al (2011) Controlled extracellular matrix degradation in breast cancer tumors improves therapy by trastuzumab. Mol Ther 19:479–489

5. Nakada T, Sugihara K, Jikoh T, Abe Y, Agatsuma T (2019) The latest research and development into the antibody-drug conjugate, [fam-] trastuzumab deruxtecan (DS-8201a), for HER2 cancer therapy. Chem Pharm Bull 67:173–185

Cited by 8 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Deep learning approaches to detect breast cancer: a comprehensive review;Multimedia Tools and Applications;2024-08-20

2. Noninvasive identification of HER2-zero, -low, or -overexpressing breast cancers: Multiparametric MRI-based quantitative characterization in predicting HER2-low status of breast cancer;European Journal of Radiology;2024-08

3. A Comprehensive Model Outperformed the Single Radiomics Model in Noninvasively Predicting the HER2 Status in Patients with Breast Cancer;Academic Radiology;2024-08

4. Development and validation of machine learning models for predicting HER2-zero and HER2-low breast cancers;British Journal of Radiology;2024-07-11

5. Identifying radiogenomic associations of breast cancer based on DCE‐MRI by using Siamese Neural Network with manufacturer bias normalization;Medical Physics;2024-06-24

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3